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Cholesterol embolization (CE) is a rare and alarming post-transplant complication,
responsible for primary non-function (PNF) or delayed graft function (DGF). Its incidence
is expected to rise due to increasingly old donors and recipients and the extended criteria
for donation. Therapy with statins and steroids has not been shown to be effective, while
agonism of prostaglandin I2 has been reported to be useful in systemic CE. We report
two cases of acute post-transplant CE in which intravenous iloprost (0.05 mg/kg/day)
was added to standard statin and steroid therapy. In the first instance, CE was due to
embolization from the kidney artery resulting in embolization of the small vessels; after a
long DGF and 15 days of iloprost therapy, renal function recovered. The second instance
is a case of embolization from the iliac artery of the recipient, where CE manifested as a
partial renal infarction. After 5 days of iloprost administration, creatinine levels improved.
Iloprost acts on vasodilation and on different inflammatory pathways, improving the
anti-inflammatory profile. Post-transplant CE is difficult to diagnose and, if not treated,
can lead to loss of function. Iloprost added to standard therapy could be beneficial in
accelerating renal function recovery immediately after transplant.
Keywords: cholesterol embolism, kidney transplant, prostaglandin agonism, delayed graft function, extended
criteria donors
INTRODUCTION
Cholesterol embolization (CE) is a rare but alarming complication in renal allograft. Its reported
frequency is roughly 0.4% (1–3) and, when it presents acutely after transplant, is recognized as one
of the causes of primary non-function (PNF) and delayed graft function (DGF) (2, 4, 5).
Considering the increase in transplants from extended criteria donors (ECDs), from donation
after circulatory death (DCD), and the tendency for recipients to be older, the possibility of
embolization arising from either donor or recipient vessels is expected to increase (6–10).
Moreover, since embolization leads to focal and patchy damage, diagnosis is difficult, and injury
severity may be underestimated (2, 11–13).
In the absence of a standard and effective therapy, strategies usually aim at stabilizing the plaque
by using statins associated with steroids if the disease is recurring and systemic. Reports describe
the effectiveness of iloprost, a synthetic analog of prostaglandin I2, as a rescue therapy in systemic
CE (2, 11, 14–16). Moreover, in the coronary angiography setting, where ischemic damage to
renal tissue is the leading pathogenic mechanism, a reduction in the incidence of contrast-induced
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nephropathy has been reported in patients with baseline renal
insufficiency undergoing coronary intervention (17).
To the best of our knowledge, there are no recent reports on
the use of iloprost in CE after kidney transplantation (2, 16, 18).
Here we report two cases of acute post-transplant CE in which
the addition of iloprost to the standard care helped accelerate the
recovery of kidney function.
Written informed consent was obtained from the participants
for the publication of these case reports.
CASE REPORT
Case 1
A 44-year-old man received a kidney transplant from a brain-
dead donor (DBD). The donor was 59 years old, had died from
cerebral hemorrhage, his Kidney Donor Profile Index (KDPI)
was 83%, Karpinsky’s score was 3, and he had been a smoker
with a past history of prostate cancer for which he was in regular
follow-up (19). The surgeon described atheromatous plaques in
the renal artery that were particularly evident at the confluence
with the aorta and were partially removed before implantation.
Immunosuppressive therapy consisted of basiliximab, steroids,
and tacrolimus. Owing to persistent oligo-anuria, a kidney
biopsy was performed on the eighth post-operative day (POD).
Histology showed severe acute tubular necrosis (ATN), diffuse
cholesterol embolism in the arterioles, inflammatory mixed
infiltrate, and interstitial edema. A borderline cellular rejection
was diagnosed, and thymoglobulin (ATG) therapy at a dose of
3 mg/kg was administered. Because of the persistence of DGF,
the kidney biopsy was repeated on POD 16. The sample showed
regression of the interstitial infiltrate, with persistence of ATN
and diffuse CE (Figure 1). Therefore, we started rescue therapy
with intravenous iloprost at a dose of 0.05 mg/kg/day for 15
days. We observed a slow but progressive recovery of kidney
function. No peripheral signs of embolism were observed on
physical examination. After 3 months, creatinine was 3 mg/dl;
at the 1 year of follow-up, it had improved to 2 mg/dl (Table 1).
In this case, the probable source of embolization was the donor
renal artery, which presented as a severe atherosclerotic plaque
at retrieval.
Case 2
A 71-year-old hypertense woman underwent a DBD double
kidney transplant. The iliac vessels of the recipient, a smoker,
presented with severe atheromatous plaques such that it was
difficult to find a suitable vessel to perform the arterial
anastomoses; some plaques were fixed to the walls of the vessel
with 6-0 prolene. The 81-year-old donor had died from a
cerebral hemorrhage, had a KDPI of 99%, and a Karpinsky’s
score of 4 in both kidneys. Immunosuppressive therapy consisted
of ATG, steroids, and tacrolimus. The graft function was
prompt, with creatinine levels of 1.7 mg/dl on POD 4, and
routine ultrasounds were normal. On POD 13, we observed
an abrupt rise in creatinine (2.4 mg/dl), lactate dehydrogenase
(LDH) 1,100 U/l, and a slight decrease in diuresis. A contrast-
enhanced ultrasonography showed a lack of vascularization in
the upper pole of one of the kidneys compatible with a partial
FIGURE 1 | Kidney biopsy at post-operative day 16. Periodic acid–Schiff
(PAS) staining, magnification 20×. Arrow indicates a massive cholesterol
embolization occluding the arteriolar lumen.
infarction. Intravenous iloprost at a dose of 0.05 mg/kg/day
was administered as a rescue therapy for 5 days. After 3
days, we started to see progressive recovery of kidney function;
after 3 months, the creatinine level was 1.5 mg/dl (Table 1).
No peripheral signs of embolism were observed on physical
examination. In this case, the most likely source of embolization
was the recipient’s iliac artery.
DISCUSSION
Atheroembolic renal disease in kidney transplantation is
recognized as a possible cause of graft loss. It can occur in
the early days post-transplant as well as in the late phases of
transplant follow-up (2, 4, 5).
When presenting acutely post-transplant, CE usually occurs
due to an acute embolization from either the aorta or the renal
artery of the donor during organ harvesting or from the vascular
axis of the recipient during surgery.
As a result of the increasing number of ECD and of the aging
of both donor and recipient population, atherosclerosis of the
vascular axis of the graft and of the recipient is becoming a serious
challenge in the field of organ transplantation (20–23).
In our first case, we described the embolization of the
donor artery in which plaque disruption probably occurred
at harvesting or during the preliminary vascular manipulation
made before implantation. In the second instance, the likely cause
the acute deterioration of function was crystal embolization from
the recipient iliac artery. Our final diagnosis was difficult to prove
since no peripheral or systemic signs of CEwere present, no other
causes of acute kidney injury were identified, and an ischemic
area was clearly identified by contrast-enhanced ultrasound. We
were aware that the patient was severely atherosclerotic from
the results of multiple computed tomography-angiographies
performed during the time spent on the waiting list. The surgeon,
due to our experience in high atherosclerotic patients, defined her
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TABLE 1 | Clinical course of both cases.
Case 1 Case 2
Post-surgery Pre-iloprost During iloprost After iloprost Post-surgery Pre-iloprost During iloprost After iloprost
Blood pressure (mmHg) 130/65 130/80 120/80 110/70 140/85 130/70 140/80
Urine volume (ml/day) 0 0 1,200 2,000 1,500 1,000 1,200 1,200
Creatinine (mg/dl) 8 8.2 8 3 1.4 2.4 2 1.6
Urea (mg/dl) 118 169 157 90 54 78 81 73
Eosinophils 109/L 0.14 0 0.15 0.07 0.06 0.16 0.22 0.09
LDH U/L 357 302 349 250 370 1193 540 402
to be suitable for transplant; her condition, however, was found
to be worse than predicted.
When the plaque disrupts, microemboli spray downstream,
and occlude the vascular lumen of small arteries. The ensuing
damage is a combination of tissue ischemia, direct cytotoxic
effects of crystals, and necrosis due to the local inflammatory
reaction. Soon after embolization, the first damage occurs to
endothelium mitochondria (24). Then, because of the large
dimensions of cholesterol crystals (1 µm−1mm), macrophages
are not able to digest them completely; this “frustrated
phagocytosis” triggers an intracellular danger signal mediated
by damage-associated molecular patterns, interleukin (IL)-1α,
IL-1β, and nuclear factor (NF)-κB (24–27). The vicious cycle
of necroinflammation eventually leads to necrosis (28, 29).
Moreover, it has been demonstrated that cholesterol crystals
also activate the complement-dependent inflammasome and
cytokines (30, 31). Overall, the ischemic and inflammatory
pathways activated by this phenomenon increase the already
high cardiovascular and inflammatory risk profile of transplant
recipients (32).
Since the damage caused by CE is patchy, it is well-known
that histologic diagnosis is difficult and often underestimated;
this also occurs in native kidneys (12, 13). Moreover, cholesterol
crystals are not always present in the sample, and the only
lesions seen are ATN and inflammatory infiltrates (2). In light
of this, the mild interstitial mixed infiltrate already present in the
biopsy of our first case could be explained as related more to an
inflammatory reaction to the severe and diffuse embolism rather
than to cellular rejection, especially considering the ischemic
lesions present in the sample.
Given the key role of inflammation in CE, therapies have
always been based on adding steroids to statins, although there
is no clear evidence of its effectiveness (2). There are also very
few reports showing positive results in the use of the synthetic
prostacyclin iloprost as a rescue therapy in systemic CE (2,
11, 14–16, 33, 34). Recently, prophylactic intravenous iloprost
therapy has shown some effectiveness in reducing the incidence
of contrast-induced nephropathy in the coronary angiography
setting in patients with baseline renal insufficiency undergoing
coronary intervention, a setting in which toxic ischemic damage
is the leading pathogenic event to renal cells (17).
In the 80s and 90s, scientific literature put great emphasis on
the prostacyclin system and on the use of prostacyclin analogs
in kidney disease (14, 35, 36). The main application field was
ischemic injury, but there are also some reported experiences in
the field of transplantation. In fact, pretransplant graft perfusion
or administration of iloprost in the early days post-transplant
led to some benefits in cases of DGF and of cyclosporin-induced
toxicity (18, 35, 37–40).
Regarding CE in kidney transplantation, there are no reports
exploring the effectiveness of PGI2 agonism.
Iloprost is an analog to PGI2 that exerts different effects
both on the vascular wall and blood cells. Acting directly on
endothelial cells, smooth muscle, and adventitia, it stimulates
angiogenesis, endothelial cell integrity, and relaxation of
smooth muscle cells. Moreover, PGI2 has inhibitory effects
on the activation of endothelial cells and on the proliferation
and migration of smooth muscle cells (41–43). PGI2 acts on
leukocytes stimulating the production of anti-inflammatory
cytokines and inhibiting the release of IL-1, tumor necrosis
factor (TNF)-α, and interferon (IFN)-γ. PGI2 also regulates
macrophage functions, promoting their anti-inflammatory
profile (44, 45). Effects on the inhibition of platelet aggregation
have also been described (20, 43).
The acute continuous iloprost therapy we administered
to our patients may have partially counteracted the
necroinflammation and vasoconstriction caused by the emboli
through vasodilatation, the inhibition of IL-1 and TNF, and
the production of other cytokines; in combination with high
steroid doses commonly used in the early post-transplant phases,
iloprost may have strengthened the positive effects that the
reduction of oxidative damage exerts on the outcome of the
transplant (46).
Our cases are a good example of increasingly common
complications related to detrimental vascular characteristics of
grafts and recipients. Moreover, in the case of transplantation,
this phenomenon could be restricted to the graft, without
the occurrence of peripheral or systemic lesions. Since the
embolization could be patchy, the pathognomonic lesion could
be invisible in the histologic sample, making the final diagnosis
even more difficult. It is important to note that the only lesion
seen at biopsy could be ATN associated with an inflammatory
infiltrate, easily attributable to cellular rejection (2).
CONCLUSIONS
Acute post-transplant CE seems to be increasingly diagnosed
in patients with severe atherosclerosis and ECD donors. In the
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context of transplantation, diagnosis can be difficult since CE can
be limited to the graft and the histology can be confused with
cellular rejection. As prompt treatment can help in reducing the
risk of PNF and in the recovery of function, CE should always be
suspected in cases of persistent DGF or acute cellular rejection
not responding to therapy. Iloprost, with its vasodilator and
anti-inflammatory effects, could potentially act on the molecular
pathways activated by cholesterol crystals; it is our opinion that
prompt intravenous therapy with iloprost, added to statins and
steroids, has accelerated the good outcome of the two patients
whose cases we have described in this report.
Of course, the effectiveness of iloprost infusion in hindering
the inflammatory and ischemic cascades induced by CE in
the immediate post-transplant setting should be investigated
in depth, especially considering that prompt intervention is
essential. Larger case control studies and clinical trials are needed
to prove the causality between iloprost administration and the
improvement of kidney function and investigate when prompt
intervention is essential.
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